Compare Quest Diagnostics Inc (DGX) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Quest Diagnostics Inc trades at $231.8 (market cap $25.48B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $67.9 (market cap $7.43B). The key difference: Quest Diagnostics Inc is far larger — about 3.4× Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 0 Days on average.
| DGX | VIST | |
|---|---|---|
Market Cap | $25.48B | $7.43B |
Volume | 941,866 | 875,552 |
Sector | Health | Energy |
52-Week High | $247.45 | $79.25 |
52-Week Low | $173.49 | $35.02 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $31.23B | $10.58B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
